Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 2/20 | 0.37 |
| ▸ | SLC8A1 | P32418 | 8/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | HTR1D | P28221 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12556044 | 0.81 | ESR1 (0.40) | ESR1ESR2ALDH1A1MAPT | |
| SCHEMBL16856814 | 0.80 | SNRNP200 (0.52) | SNRNP200SLC8A1ESR1ESR2 | |
| SCHEMBL1933116 | 0.78 | ESR1 (0.40) | SNRNP200SLC8A1ESR1ESR2DDB1 | |
| SCHEMBL6292853 | 0.77 | HTR1A (0.45) | DDB1CRBNALDH1A1HTR1AHTR1D | |
| SCHEMBL6291943 | 0.75 | ESR1 (0.59) | SLC8A1ESR1ESR2ALDH1A1 | |
| SCHEMBL11039123 | 0.75 | ESR1 (0.43) | SLC8A1ESR1ESR2ALDH1A1 | |
| SCHEMBL6296267 | 0.75 | ESR2 (0.59) | ESR1ESR2 | |
| SCHEMBL13820745 | 0.75 | FFAR1 (0.42) | ESR1ESR2 | |
| SCHEMBL16857079 | 0.72 | SNRNP200 (0.51) | SNRNP200SLC8A1DDB1CRBNALDH1A1 | |
| SCHEMBL13720329 | 0.71 | LPL (0.35) | SNRNP200ESR1ESR2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | PTGIS, LIPG, FEN1 | SNRNP200 3216/4885SLC8A1 1449/4885ESR1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.